Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Selinexor	Xpovio	KPT-330	XPO1 Inhibitor 4	Xpovio (selinexor) inhibits CRM1 (XPO1), preventing CRM1-mediated nuclear export of tumor suppressor proteins and potentially restoring normal tumor suppressor function (PMID: 30976603, PMID: 31793336). Xpovio (selinexor) is FDA approved for use in patients with diffuse large B cell lymphoma after two or more prior therapies, in combination with Adexone (dexamethasone) in patients with relapsed or refractory multiple myeloma after at least four prior therapies, and in combination with Velcade (bortezomib) and Adexone (dexamethasone) in patients with multiple myeloma after at least one prior therapy (FDA.gov).

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
TET2 del	acute myeloid leukemia	sensitive	Selinexor	Preclinical - Cell culture	Actionable	In a preclinical study, Xpovio (selinexor) induced apoptosis in TET2-knockout acute myeloid leukemia cell lines, resulting in decreased cell viability in culture (PMID: 36746437).	36746437
TP53 loss	thymoma	predicted - resistant	Selinexor	Preclinical - Cell culture	Actionable	In a preclinical study, a thymoma cell line with TP53 loss demonstrated primary resistance to Selinexor (KPT-330) in culture, and reconstitution of TP53 expression resulted in increased Selinexor sensitivity (PMID: 28819023).	28819023

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02227251	Phase II	Selinexor	Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Recruiting	USA \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BGR \| BEL \| AUT \| AUS	2
NCT02250885	Phase II	Selinexor	KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors	Completed	USA	0
NCT02536495	Phase Ib/II	Docetaxel Selinexor	Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer	Withdrawn		0
NCT02402764	Phase II	Selinexor	Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC	Completed	USA	0
NCT07200102	Phase I	Selinexor	Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma	Not yet recruiting	USA	0
NCT03193437	Phase II	Selinexor	Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy	Terminated	USA	0
NCT02228525	Phase II	Selinexor	Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes	Completed	USA	0
NCT05985161	Phase II	Selinexor	A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors	Recruiting	USA	0
NCT02091245	Phase I	Selinexor	Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML	Active, not recruiting	USA	0
NCT04421378	Phase Ib/II	Lomustine + Selinexor Lomustine Selinexor + Temozolomide Temozolomide Selinexor	A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma	Terminated	USA \| CAN	0
NCT02606461	Phase II	Selinexor	KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL)	Completed	USA \| SWE \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL	0
NCT02471911	Phase I	Dexamethasone Carboplatin + Etoposide + Ifosfamide + Rituximab Selinexor	KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma	Completed	USA	0
NCT04854434	Phase II	Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor	A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations	Terminated	USA	0
NCT05597345	Phase II	Selinexor	Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma	Recruiting	USA	0
NCT05099003	Phase Ib/II	Selinexor	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	Recruiting	USA \| NZL \| CAN \| AUS	0
NCT05611931	Phase III	Selinexor	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)	Recruiting	USA \| TUR \| SVK \| ITA \| ISR \| IRL \| HUN \| GRC \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS	3
NCT02215161	Phase II	Selinexor	Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide	Terminated	USA	0
NCT02416908	Phase Ib/II	Selinexor Cladribine + Cytarabine + Plerixafor	Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia	Completed	USA	0
NCT01607905	Phase I	Selinexor	Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer	Completed	USA \| DNK \| CAN	0
NCT04811196	Phase I	Selinexor	A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients	Completed	CAN	0
NCT06813079	Phase II	Abemaciclib Ceritinib Selinexor Doxorubicin Etoposide Brigatinib Ponatinib Neratinib Cobimetinib	Using Tumor Models to Determine Treatments	Not yet recruiting	CAN	0
NCT06822972	Phase II	Selinexor	HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM	Recruiting	USA	0
NCT04256707	Phase Ib/II	Pembrolizumab + Selinexor Docetaxel + Selinexor Fluorouracil + Irinotecan + Leucovorin + Selinexor Selinexor	Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)	Completed	ISR	0
NCT02419495	Phase I	Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin	Selinexor in Combination With Standard Chemotherapy	Terminated	USA	0
NCT02403310	Phase I	Cytarabine + Daunorubicin Selinexor	A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML	Completed	USA	0
NCT02120222	Phase I	Selinexor	Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery	Completed	USA	0
NCT03555422	Phase III	Selinexor	Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO)	Active, not recruiting	USA \| ITA \| ISR \| GRC \| ESP \| DEU \| CZE \| CAN \| BEL	1
NCT03627403	Phase II	Selinexor	Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)	Terminated	USA	0
NCT02088541	Phase II	Cytarabine Azacitidine Decitabine Selinexor Hydroxyurea	Selinexor (KPT-330) in Older Patients With Relapsed AML	Completed	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN	0
NCT02069730	Phase I	Selinexor	A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes	Completed	CAN	0
NCT02323880	Phase I	Selinexor	Study of Selinexor in Pediatric Solid Tumors	Completed	USA	0
NCT02351505	Phase II	Selinexor	Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer	Terminated	USA	0
NCT06239272	Phase Ib/II	Selinexor Pazopanib Doxorubicin + Ifosfamide	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)	Recruiting	USA	0
NCT02146833	Phase II	Selinexor	Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma	Terminated	USA	0
NCT02138786	Phase II	Selinexor	Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)	Terminated	USA \| POL \| GBR \| ESP \| DEU	0
NCT02212561	Phase Ib/II	Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine	Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome	Completed	USA	0
NCT02485535	Phase I	Selinexor	Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	Completed	USA	0
NCT01986348	Phase II	Selinexor	Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide	Terminated	USA \| NLD \| DNK	0
NCT02299518	Phase I	Etoposide Selinexor Cytarabine + Etoposide + Mitoxantrone	Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	USA	0
NCT03147885	Phase Ib/II	Selinexor	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT02573363	Phase I	Cytarabine Mitoxantrone Selinexor	Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia	Completed	USA	0

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST